Platelet-activating factor primes human eosinophil generation of superoxide.

Platelet-activating factor (PAF) is a potent inflammatory mediator that can cause airway obstruction and hyperresponsiveness; these processes are also associated with pulmonary eosinophilia, suggesting a link between these two events. Thus, PAF's interaction with eosinophils may provide a mechanism for airway damage. However, direct in vitro activation of eosinophils by PAF requires concentrations that are likely higher than those achieved in vivo. As a result, we investigated whether lower, more physiologic concentrations of PAF could prime eosinophils for subsequent activation to another receptor-stimulated factor, in this case formylmethionylleucylphenylalanine (FMLP). To test this hypothesis, eosinophils were preincubated (1 and 15 min) with low concentrations of PAF (1 x 10(-8) and 1 x 10(-10) M); this exposure to PAF resulted in enhanced generation of superoxide anion to FMLP stimulation. Moreover, similar concentrations of PAF decreased eosinophil density and increased expression of cell surface CR3 receptors. Finally, low, nonactivating concentrations of PAF (1 x 10(-10) to 1 x 10(-8) M) caused transient increases in eosinophil cytosolic free Ca2+ concentrations. Collectively, these responses are consistent with the hypothesis that short-term exposure to low concentrations of PAF primes eosinophils to cause an enhanced inflammatory response upon subsequent activation to another receptor agonist. The consequences of this PAF-associated phenomenon can produce an enhanced inflammatory response and airway injury.

[1]  W. Busse,et al.  Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. , 1991, The American review of respiratory disease.

[2]  W. Busse,et al.  The effect of platelet-activating factor on the generation of superoxide anion in human eosinophils and neutrophils. , 1991, The Journal of allergy and clinical immunology.

[3]  R. Folkerth,et al.  Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Barnes,et al.  Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. Concerted biosynthesis of thromboxane A2 and E-series prostaglandins. , 1990, Journal of immunology.

[5]  K. Chung,et al.  The effects of activated eosinophils and neutrophils on guinea pig airway epithelium in vitro. , 1990, American journal of respiratory cell and molecular biology.

[6]  C. Nathan,et al.  Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrins , 1989, The Journal of cell biology.

[7]  W. Busse,et al.  The appearance of hypodense eosinophils in antigen-dependent late phase asthma. , 1989, The American review of respiratory disease.

[8]  K. Chung,et al.  Stimulation of degranulation from human eosinophils by platelet-activating factor. , 1989, Journal of immunology.

[9]  J. O'flaherty,et al.  Bidirectional effects of protein kinase C activators. Studies with human neutrophils and platelet-activating factor. , 1989, The Journal of biological chemistry.

[10]  L. Koenderman,et al.  Dual mechanisms in priming of the chemoattractant-induced respiratory burst in human granulocytes. A Ca2+-dependent and a Ca2+-independent route. , 1989, Journal of immunology.

[11]  C. Nathan Respiratory burst in adherent human neutrophils: triggering by colony- stimulating factors CSF-GM and CSF-G , 1989 .

[12]  J. Gay,et al.  Enhancement of phorbol ester‐induced protein kinase activity in human neutrophils by platelet‐activating factor , 1988, Journal of cellular physiology.

[13]  B. Zweiman,et al.  Platelet Activating Factor Increases Expression of Complement Receptors on Human Neutrophils , 1988, Journal of leukocyte biology.

[14]  S. Wright,et al.  Adhesion-promoting receptors on leukocytes. , 1988, Current opinion in immunology.

[15]  W. Owen,et al.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.

[16]  W. Busse,et al.  Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. , 1988, The Journal of allergy and clinical immunology.

[17]  P. Henson,et al.  Stimulation of eosinophil adherence to human vascular endothelial cells in vitro by platelet-activating factor. , 1988, Journal of immunology.

[18]  A. Denjean,et al.  Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge. Inhibition by ketotifen. , 1988, The American review of respiratory disease.

[19]  G. Vercellotti,et al.  Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage. , 1988, Blood.

[20]  C. Page,et al.  The role of platelet-activating factor in asthma. , 1988, The Journal of allergy and clinical immunology.

[21]  P. Barnes Platelet-activating factor and asthma. , 1988, The Journal of allergy and clinical immunology.

[22]  G. Dabiri,et al.  Platelet-activating factor both stimulates and "primes" human polymorphonuclear leukocyte actin filament assembly. , 1987, Blood.

[23]  C. Nathan Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. , 1987, The Journal of clinical investigation.

[24]  R. Patterson,et al.  The bronchoconstrictor properties of platelet-activating factor in humans. , 1987, The American review of respiratory disease.

[25]  W. Owen,et al.  Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts , 1987, The Journal of experimental medicine.

[26]  J. Bousquet,et al.  Bronchoalveolar lavage in the asthmatic. , 1987, Bulletin europeen de physiopathologie respiratoire.

[27]  A. Wardlaw,et al.  Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. , 1986, The Journal of clinical investigation.

[28]  L. Koenderman,et al.  Platelet-activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. , 1986, Pharmacological research communications.

[29]  F. Cuss,et al.  EFFECTS OF INHALED PLATELET ACTIVATING FACTOR ON PULMONARY FUNCTION AND BRONCHIAL RESPONSIVENESS IN MAN , 1986, The Lancet.

[30]  J. Lukens,et al.  Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor. , 1986, Blood.

[31]  B. Seligmann,et al.  Exudation primes human and guinea pig neutrophils for subsequent responsiveness to the chemotactic peptide N-formylmethionylleucylphenylalanine and increases complement component C3bi receptor expression. , 1986, The Journal of clinical investigation.

[32]  B. Dewald,et al.  Activation of NADPH oxidase in human neutrophils. Synergism between fMLP and the neutrophil products PAF and LTB4. , 1985, Biochemical and biophysical research communications.

[33]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[34]  D. Macdonald,et al.  Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf‐acether) in mang , 1985, The British journal of dermatology.

[35]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[36]  H. Mita,et al.  Release of leukotriene C4 from human eosinophils and its relation to the cell density. , 1985, International archives of allergy and applied immunology.

[37]  Berger,et al.  Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. , 1984, The Journal of clinical investigation.

[38]  D. Lenihan,et al.  Increased biosynthesis of platelet-activating factor in activated human eosinophils. , 1984, The Journal of biological chemistry.

[39]  D. Macdonald,et al.  Inflammatory characteristics of platelet activating factor (PAF‐acether) in human skin , 1984, The British journal of dermatology.

[40]  A. Capron,et al.  Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. , 1983, International archives of allergy and applied immunology.

[41]  J. Lukens,et al.  Regulation of human polymorphonuclear leukocyte superoxide release by cellular responses to chemotactic peptides. , 1981, Journal of immunology.

[42]  J. Benveniste,et al.  Release of platelet‐activating factor (PAF‐acether) from alveolar macrophages by the calcium ionophore A 23187 and phagocytosis , 1980, European journal of clinical investigation.

[43]  J. Egido,et al.  Platelet-activating factor in anaphylaxis and phagocytosis. I. Release from human peripheral polymorphonuclears and monocytes during the stimulation by ionophore A23187 and phagocytosis but not from degranulating basophils. , 1980, Immunology.

[44]  D. V. Van Epps,et al.  Enhancement of neutrophils function as a result of prior exposure to chemotactic factor. , 1980, The Journal of clinical investigation.